\begin{tabular}{lllll}
\toprule
Domain & Durvalumab, n (\%) & Atezolizumab, n (\%) & Adjusted OR (95\% CI) & FDR q value \\
\midrule
Pulmonary & 707 (11.5) & 653 (7.5) & 1.63 (1.44, 1.85) & <0.001 \\
Renal & 55 (0.9) & 266 (3.0) & 0.36 (0.26, 0.48) & <0.001 \\
Hepatobiliary & 137 (2.2) & 417 (4.8) & 0.57 (0.47, 0.71) & <0.001 \\
Neurologic & 63 (1.0) & 181 (2.1) & 0.48 (0.35, 0.65) & <0.001 \\
Hematologic & 153 (2.5) & 411 (4.7) & 0.71 (0.58, 0.87) & 0.003 \\
Gastrointestinal & 121 (2.0) & 303 (3.5) & 0.69 (0.54, 0.87) & 0.004 \\
Dermatologic & 231 (3.8) & 468 (5.3) & 0.81 (0.68, 0.97) & 0.032 \\
Cardiac & 136 (2.2) & 258 (2.9) & 0.83 (0.66, 1.04) & 0.167 \\
Endocrine & 253 (4.1) & 450 (5.1) & 0.91 (0.76, 1.08) & 0.323 \\
Generalized Immune Mediated & 24 (0.4) & 53 (0.6) & 0.74 (0.44, 1.26) & 0.323 \\
Musculoskeletal & 130 (2.1) & 223 (2.5) & 0.99 (0.78, 1.26) & 0.929 \\
Ocular & 10 (0.2) & 15 (0.2) & 0.96 (0.38, 2.42) & 0.929 \\
\bottomrule
\end{tabular}
